New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2014
08:08 EDTMMM, NVSEMA committee recommends approval for 3M rivastigmine patch
The EMA's Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Rivastigmine transdermal patches intended for symptomatic treatment of mild to moderately severe Alzheimer's dementia. The applicant for this medicinal product is 3M Health Care (MMM). Rivastigmine 3M Health Care Ltd is a generic of Novartis' (NVS) Exelon.
News For MMM;NVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 23, 2014
12:20 EDTMMMOn The Fly: Midday Wrap
Subscribe for More Information
11:57 EDTNVSNovartis management to meet with Jefferies
Subscribe for More Information
09:30 EDTMMM3M Company says 'on track' for sales, income growth targets
Subscribe for More Information
09:04 EDTMMMOn The Fly: Pre-market Movers
Subscribe for More Information
08:51 EDTMMM3M Company now sees FY14 tax rate 28.5%-29%
Prior view was 28%-29%. Comments from slides that will be presented on the Q3 earnings conference call.
07:34 EDTMMM3M Company sees 2014 EPS $7.40-$7.50 vs. previous $7.30-$7.55
Subscribe for More Information
07:32 EDTMMM3M Company reports Q3 EPS $1.98, consensus $1.96
Reports Q3 revenue $8.14B, consensus $8.24B.
05:21 EDTNVSNovartis AIN457 meets primary endpoint in two Phase III studies in AS
Novartis announced that AIN457 met primary and key secondary endpoints in two pivotal Phase III studies, MEASURE 1 and MEASURE 2, in patients with ankylosing spondylitis, or AS. Key endpoints included improvements in signs and symptoms of the disease versus placebo and associated improvements in physical function and quality of life. Secukinumab is an investigational medicine that works by stopping the action of interleukin- 17A, a protein that is central to the development of inflammatory diseases, including AS. MEASURE 1 and MEASURE 2 enrolled a combined total of approximately 600 patients. Detailed results of the studies will be presented at an upcoming medical congress. Joint regulatory applications for secukinumab in AS and PsA are planned for 2015. This follows the secukinumab global regulatory applications for moderate- to-severe plaque psoriasis which were filed in October 2013 with regulatory decisions anticipated in late 2014 or early 2015.
October 22, 2014
15:37 EDTMMMNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Comcast (CMCSA), consensus 71c; Union Pacific (UNP), consensus $1.52; 3M (MMM), consensus $1.96; AbbVie (ABBV), consensus 77c; Celgene (CELG), consensus 95c; Eli Lilly (LLY), consensus 67c; Occidental Petroleum (OXY), consensus $1.57; Caterpillar (CAT), consensus $1.36; Alexion Pharmaceuticals (ALXN), consensus $1.16; Precision Castparts (PCP), consensus $3.32; Raytheon (RTN), consensus $1.60; American Electric Power (AEP), consensus $1.02; Southwest Airlines (LUV), consensus 53c; Lorillard (LO), consensus 90c; T. Rowe Price (TROW), consensus $1.15; Mead Johnson (MJN), consensus 91c; Zimmer Holdings (ZMH), consensus $1.30; Nucor (NUE), consensus 73c; Nielsen (NLSN), consensus 65c; Prologis (PLD), consensus 46c; Sigma-Aldrich (SIAL), consensus $1.06; Under Armour (UA), consensus 40c; EQT (EQT), consensus 56c; Dr Pepper Snapple (DPS), consensus 88c; Cameron International (CAM), consensus $1.10; Coca-Cola Enterprises (CCE), consensus 89c; Quest Diagnostics (DGX), consensus $1.08; CMS Energy (CMS), consensus 41c; Airgas (ARG), consensus $1.29; PulteGroup (PHM), consensus 36c; Diamond Offshore (DO), consensus 79c; Bemis (BMS), consensus 67c.
14:26 EDTMMM3M Company technical preview before earnings
In the prior three months the shares have moderately underperformed the broader averages. The trend had been sharply down from mid-September until the recent market rebound. The prior three months saw the shares hit its all time life high at $147.87. On better than expected results, a retest to that area would be highly probable although there is substantial resistance at the $145 area. If the news disappoints, there are broader technical implications for the long-term uptrend. A big level to watch is the recent low at $130.60. If there is a disappointment, that area could be retested. A move below the $130 area would break the long-term uptrend. The $130 level has been an area of support several times in the prior year, and loss of support at that area would therefore be psychologically significant and likely bearish for future price.
09:09 EDTMMM3M Company October weekly volatility elevated into Q3 and outlook
Subscribe for More Information
07:44 EDTNVSGlaxoSmithKline backs FY14 view for core EPS 'broadly similar' to FY13
GlaxoSmithKline (GSK) continues to expect full year 2014 core EPS to be broadly similar to 2013 at CER and on ex-divestment basis. Glaxo says its proposed 3-part transaction with Novartis (NVS) is on track for completion in 1H15.
October 21, 2014
07:15 EDTNVSFDA to hold workshop on breast cancer drug development
Subscribe for More Information
October 20, 2014
15:09 EDTNVSNovartis reports FDA advisory committee recommends approval of secukinumab
Novartis announced the Dermatologic and Ophthalmic Drugs Advisory Committee to the FDA voted unanimously to support the approval of AIN457, or secukinumab, a selective interleukin-17A inhibitor, for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. A Biologics License Application for secukinumab is currently under FDA review with an anticipated action date in early 2015.
07:26 EDTNVSFDA Dermatologic & Ophthalmic Drugs Advisory Committee to hold a meeting
Subscribe for More Information
07:22 EDTMMMSolar Energy Trade Shows to hold a conference
Subscribe for More Information
October 17, 2014
14:50 EDTNVSBARDA asks labs to ramp up Zmapp production, Reuters says
Subscribe for More Information
October 15, 2014
17:03 EDTNVSNovartis announces CTL019 data demonstrating efficacy in certain ALL patients
Novartis and the University of Pennsylvania's Perelman School of Medicine announced preliminary results from two pilot clinical trials published in The New England Journal of Medicine, or NEJM, evaluating the efficacy and safety of CTL019 in patients with relapsed/refractory acute lymphoblastic leukemia, or r/r ALL. The studies, conducted by Penn, demonstrated that 27 of 30 pediatric and adult patients, or 90%, experienced complete remissions with the investigational chimeric antigen receptor, or CAR, therapy CTL019. Largest published cohort to date for CTL019, which served as the basis for recent Breakthrough Therapy designation from the FDA. Sustained remissions of up to two years in r/r ALL patients with six-month event-free survival of 67% and overall survival of 78%.
14:40 EDTMMM3M Company receives orders from U.S. government for Enhanced Combat Helmet
3M announces it has received additional orders from U.S. government for its Enhanced Combat Helmet that provide military personnel with protection against head injury from ballistic threats and blunt impacts. 3M will deliver 35,000 helmets for the U.S. Army and 2,500 helmets for the U.S. Navy in addition to the 77,000 ordered for the U.S. Marine Corps last fall. The new orders bring the total contract value for Enhanced Combat Helmets and associated spare parts to $107M. This contract for over 114,000 helmets is an outcome of the joint procurement program led by the U.S. Marine Corps and the U.S. Army to improve head protection for Marines, Soldiers and Sailors.
October 14, 2014
11:23 EDTNVSBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use